Bevacizumab blocks the autocrine and paracrine VEGF signaling and reduces vessel leakiness and pressures within the brain tumor, triggering a vasogenic edema reduction and, consequently, lowering corticosteroid administration [11, 12]. The gene discussed is VEGFA; the disease is brain neoplasm.